Tri-Cities Tech Business Update
*IsoRay signs distribution agreement
IsoRay Inc., based in Richland, Wash., has entered an agreement with BrachySciences- a division of Biocompatibles International-to distribute IsoRay's Proxcelan Cesium-131 brachytherapy seeds. The distribution agreement is designed to provide physicians with more choices and flexibility to offer patients the newest isotope available to treat prostate and other cancers. IsoRay, Inc. is the sole producer of the Cesium-131 brachytherapy seed that has a significantly shorter half-life than the two other isotopes commonly used in brachytherapy treatment. This results in a substantially faster delivery of therapeutic radiation, a lower probability of cancer cell survival, and a reduction of the longevity of common brachytherapy side effects. Contact Jonathan Hunt at (509) 375-1202.
